Search Results - "Shafagati, Nazila"

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers by Zelikson, Viktoriya, Gurumurthi, Ashwath, Sawalha, Yazeed, Annunzio, Kaitlin, Saha, Aditi, Dong, Ning, Qualls, David, Amoozgar, Behzad, Kahl, Brad, Baird, John, Challa, Pavan, Huntington, Scott F, Santos, Jennifer, Bair, Steven, Narkhede, Mayur, Li, Shuning, Frosch, Zachary, Ho, Carrie, Smith, Stephen D, Winter, Allison, Landsburg, Daniel, Furqan, Fateeha, Hamadani, Mehdi, Baird, Katelin, Romancik, Jason, Alharthy, Hanan, Law, Jennie, Bojanini, Leyla, Advani, Ranjana, Hu, Boyu, Johnson, Patrick Connor, Grover, Natalie S., Merril, Mwanasha, Crombie, Jennifer L., Shafagati, Nazila, Sterling, Cole, Nastoupil, Loretta J., Epperla, Narendranath, Ayers, Emily C

“…Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug…”
Get full text

Antibody-Based Therapies for Peripheral T-Cell Lymphoma by Shafagati, Nazila, Paul, Suman, Rozati, Sima, Sterling, Cole H

“…While antibody-based immunotherapeutic strategies have revolutionized the treatment of B-cell lymphomas, progress in T-cell lymphomas has suffered from…”
Get full text

Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis by Shafagati, Nazila, Stuver, Robert N., Boussi, Leora, Koh, Min Jung, Park, Allison, Bain, Paul, Foss, Francine M., Shen, Changyu, Jain, Salvia

“…Background: Patients with advanced peripheral and cutaneous T-cell lymphomas (PTCL and CTCL) have an unfavorable prognosis . Primary refractoriness to…”
Get full text

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers by Ayers, Emily, Zelikson, Viktoriya, Gurumurthi, Ashwath, Sawalha, Yazeed, Annunzio, Kaitlin, Saha, Aditi, Dong, Ning, Qualls, David Augustus, Amoozgar, Behzad, Kahl, Brad S., Baird, John H., Challa, Pavan, Huntington, Scott F., Santos, Jennifer, Bair, Steven M., Narkhede, Mayur S., Li, Shuning, Frosch, Zachary AK, Ho, Carrie I, Smith, Stephen D, Winter, Allison, Landsburg, Daniel J., Furqan, Fateeha, Hamadani, Mehdi, Baird, Katelin, Romancik, Jason T., Alharthy, Hanan, Law, Jennie, Bojanini, Leyla, Advani, Ranjana H., Hu, Boyu, Johnson, Patrick Connor, Grover, Natalie S., Kundu, Debamita, Merrill, Mwanasha Hamuza, Crombie, Jennifer L, Shafagati, Nazila, Sterling, Cole, Nastoupil, Loretta J., Epperla, Narendranath

“…Background: In the LOTIS-2 study, patients (pts) with relapsed/refractory (R/R) DLBCL treated with loncastuximab-tesirine (lonca), a CD19 directed…”
Get full text

Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis by Shafagati, Nazila, Koh, Min J., Boussi, Leora, Park, Hyun J., Stuver, Robert, Bain, Paul, Foss, Francine M., Shen, Changyu, Jain, Salvia

“…Optimal treatment strategies for (relapsed and refractory [R/R]) peripheral T-cell lymphoma (PTCL) have not been well defined, and with the approval of several…”
Get full text